Overview
Study of Fat Malabsorption by Lipiblock Versus Xenical
Status:
Completed
Completed
Trial end date:
2010-04-01
2010-04-01
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
Obesity is a chronic condition with fat-rich diets playing a major role in its etiology. Pharmacological therapy has been proposed for weight loss and maintenance. This study aims to study the intestinal lipase blockade by partial inhibition of fat absorption after treatment with two commercials formulations of Orlistat.Phase:
N/AAccepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
University of Campinas, BrazilCollaborator:
Germed PharmaTreatments:
Orlistat
Criteria
Inclusion Criteria:- Obesity
- BMC (Body Mass Index) between 30 to 40 kg/m2
- Women
- 18 to 45 years
- Premenopausal stage
Exclusion Criteria:
- Relevant diseases (diabetes, cardiovascular, gastrointestinal, renal and hepatic
diseases, endocrine disorders, hemoglobinopatHy or neoplasm in the last three years)
- Chemical or natural laxatives
- Weight variation greater than 5% in the preceding 3 months
- Surgery for weight reduction
- Drugs to obesity control and/or oral corticosteroids anti-inflammatory in the last
three months